一种现场自凝聚的多酸液体粘合剂形成了对性结肠炎治疗的抗病原体屏障
Xinrui Zhao1, Fushuo Wang1, Yage Sun1
1School of Materials Science and Engineering, State Key Laboratory of Precious Metal Functional Materials, Tianjin University, Tianjin 300350, China.
ACS nano
|November 12, 2025
概括
一种新型的自我固化的液体粘合剂,聚脂酸液体粘合剂 (PLALA),通过形成保护性屏障,增强粘液透,并恢复肠道健康,有效地治疗性结肠炎.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 纳米技术 纳米技术
背景情况:
- 性结肠炎 (UC) 涉及炎症,屏障功能障碍和肠道微生物群不平衡.
- 目前用于UC的纳米药物输送面临着诸如目标不良,粘液透和溶解体捕获等挑战.
研究的目的:
- 设计一种自我固化,粘液模仿的多酸液体粘合剂 (PLALA),以克服UC中的纳米药物输送限制.
- 在性结肠炎的临床前模型中评估PLALA的治疗疗效.
主要方法:
- 通过生物无害的水性组合途径合成了PLALA,形成棒状的酸 (LANa) 粒.
- 普拉拉被设计用于现场固化,静电粘膜粘附和释放基于脂质的纳米细胞.
- 在UC的老鼠模型中评估了PLALA的疗效,评估了屏障恢复,炎症和微生物群.
主要成果:
- 普拉拉证明了对炎症的粘膜的选择性粘附和在现场固化成持久的屏障.
- 释放的纳米细胞有效地穿透了粘液并实现了细胞质的传递,增强了抗氧化作用并抑制了亡.
- 在大鼠UC模型中,PLALA治疗恢复了上皮屏障,减少了炎症,并调节了微生物群.
结论:
- 普拉拉为性结肠炎治疗提供了一种无药,改变范式的策略.
- 开发的材料克服了传统纳米药物用于炎症性肠道疾病的关键限制.
- 通过屏障修复和微生物群重塑,PLALA显示出治疗耐火性炎症性肠病的巨大潜力.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
439
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
439
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
01:21Inflammatory Bowel Disease V: Surgical Management
430
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
430
01:21Drugs for Treatment of Constipation-Predominant IBS
686
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
686
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
459